Bicycle Therapeutics PLC
NASDAQ:BCYC

Watchlist Manager
Bicycle Therapeutics PLC Logo
Bicycle Therapeutics PLC
NASDAQ:BCYC
Watchlist
Price: 20.54 USD 1.38% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Bicycle Therapeutics PLC?
Write Note

Bicycle Therapeutics PLC
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bicycle Therapeutics PLC
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Bicycle Therapeutics PLC
NASDAQ:BCYC
Cash & Cash Equivalents
$890.9m
CAGR 3-Years
51%
CAGR 5-Years
56%
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Cash & Cash Equivalents
$128m
CAGR 3-Years
161%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Exscientia PLC
NASDAQ:EXAI
Cash & Cash Equivalents
ÂŁ257.6m
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Cash & Cash Equivalents
$239.6m
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Cash & Cash Equivalents
ÂŁ442.6m
CAGR 3-Years
51%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Cash & Cash Equivalents
ÂŁ42.5m
CAGR 3-Years
-3%
CAGR 5-Years
7%
CAGR 10-Years
6%
No Stocks Found

Bicycle Therapeutics PLC
Glance View

Market Cap
1.4B USD
Industry
Biotechnology

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 119 full-time employees. The company went IPO on 2019-05-23. The firm is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC) targeting EphA2, and BT8009, a second-generation BTC targeting Nectin-4, a tumor antigen in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets membrane type 1 matrix metalloproteinase (MT1-MMP) is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the center for drug development of cancer research United Kingdom. The Company’s immune-oncology products include BT7480, BT7455 and BT7401. BT7480 is a TICA that targets CD137 and Nectin-4. BT7455 is a TICA targeting EphA2 and CD137. BT7401 is an agonistic Bicycle built from multiple CD137 monomeric Bicycles.

BCYC Intrinsic Value
10.81 USD
Overvaluation 47%
Intrinsic Value
Price

See Also

What is Bicycle Therapeutics PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
890.9m USD

Based on the financial report for Sep 30, 2024, Bicycle Therapeutics PLC's Cash & Cash Equivalents amounts to 890.9m USD.

What is Bicycle Therapeutics PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
56%

Over the last year, the Cash & Cash Equivalents growth was 56%. The average annual Cash & Cash Equivalents growth rates for Bicycle Therapeutics PLC have been 51% over the past three years , 56% over the past five years .

Back to Top